Bayer drug fails Phase 3 trial


Bayer's (BAYRY) cancer drug Nexavar (sorafenib)  fails to meet its primary endpoint of improving recurrence-free survival.

The target patient group is liver cancer patients who had no detectable disease after surgery.

The company states that it remains committed to exploring the full potential of the drug in all stages of liver cancer.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs